NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
99.98% Shareholder Approval for Fundraise via Qualified Institutions Placement (QIP)
Shareholders of Gujarat Themis Biosyn have approved a special resolution to raise funds through a Qualified Institutions Placement (QIP). The proposal received overwhelming support with 99.9762% of votes cast in favor, representing 72.96% of the total share capital. This capital raise is intended to support the company's strategic goal of doubling fermentation capacity from 216 MT to 432 MT by FY26. While the specific fundraise amount was not disclosed in this voting report, the approval is a critical step for the company's expansion into higher-value APIs.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders have officially authorized the company to raise capital through a QIP, clearing the regulatory path for institutional fund infusion.
ஏன் இது முக்கியம்The fundraise is essential for financing the company's 100% capacity expansion and its transition into a higher-value API manufacturer, aiming for a revenue target exceeding Rs 250 Cr.
📅 குறுகிய காலம்Positive sentiment expected as the company secures shareholder backing for growth capital; focus will now shift to institutional demand and pricing of the QIP.
📈 நீண்ட காலம்Structurally significant if the capital is used to successfully double capacity and diversify the product mix, potentially reducing the current 98% revenue concentration from two clients.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution for existing shareholders
High client concentration (98% revenue from two clients)
👀 கவனிக்க வேண்டியவை
Monitor upcoming board announcements regarding the QIP floor price and the total quantum of funds to be raised. Track the deployment of these funds toward the fermentation capacity expansion and the stabilization of the new API unit.
GUJTHEM to Acquire Sanofi Portfolio for €158M and MicroBiopharm Japan (INR 561 Cr Revenue)
Gujarat Themis Biosyn (GTBL) has announced two transformative acquisitions: Sanofi’s anti-TB portfolio for €158 million and MicroBiopharm Japan (MBJ) with FY26 revenues of JPY 9.5 Bn (~INR 561.82 Cr). These acquisitions represent a massive scale-up, as the combined target revenues are approximately 6.7x GTBL's FY26 revenue of INR 165.82 Cr. Additionally, the company has doubled its fermentation capacity to 990 KL in FY26 and completed forward integration into APIs. While growth prospects are significant, the €158 million deal value is nearly 4.8x the company's FY26 net worth of INR 287.77 Cr, indicating a major funding requirement.
உச்சம் நம்பிக்கை
என்ன மாறியதுGTBL is transitioning from a domestic fermentation intermediate manufacturer into a global CDMO and branded pharmaceutical platform through two large-scale international acquisitions.
ஏன் இது முக்கியம்The acquisitions provide immediate access to regulated markets (Europe, Japan) and high-value therapeutic areas like oncology and biologics, potentially re-rating the company from a small-cap supplier to a global player.
📅 குறுகிய காலம்The market is likely to react positively to the massive expansion in scale and global footprint, though details on funding the €158m acquisition will be a key focus.
📈 நீண்ட காலம்If successfully integrated, these acquisitions structurally transform GTBL into a diversified global pharma entity with proprietary technology in fermentation and biologics.
⚠ அபாய எச்சரிக்கைகள்
Significant funding requirement for €158m deal relative to net worth
High execution risk in integrating Japanese and European operations
Current high customer concentration (98% of revenue from two clients)
👀 கவனிக்க வேண்டியவை
Monitor the regulatory approval timeline for both acquisitions and the specific financing structure (debt vs. equity) for the €158 million Sanofi deal. Watch for the successful integration of MBJ's advanced biotech capabilities like ADCs and Plasmids into GTBL's existing fermentation platform.
Gujarat Themis Biosyn Initiates ₹90.24 Crore Arbitration Against Optimus Drugs
Gujarat Themis Biosyn Limited (GTBL) has initiated arbitration proceedings against Optimus Drugs Private Limited for the wrongful termination of a supply agreement. The company is seeking a total recovery of approximately ₹90.24 crores, primarily driven by a ₹75 crore claim for breach of 'Take-or-Pay' obligations. Additionally, the company is claiming ₹15 crores in damages and ₹23.81 lakhs for interest on delayed payments. As GTBL is the claimant, the management does not expect any negative financial implications or penalties from this proceeding.
முக்கிய அம்சங்கள்
Initiated arbitration against Optimus Drugs Private Limited for breach of contract terms.Claiming ₹75.00 crore in break fees due to violation of mandatory 'Take-or-Pay' purchase obligations.Seeking ₹15.00 crore towards general damages and financial losses resulting from the termination.Additional claim of ₹23.81 lakh for interest on delayed payments plus ongoing interest.Management confirms no expected financial liability as the company is the party seeking recovery.
👀 கவனிக்க வேண்டியவை
Investors should view this as a potential long-term cash flow catalyst, though arbitration outcomes can take significant time to materialize. Monitor future disclosures for the tribunal's interim orders or final settlement terms.
Gujarat Themis Biosyn Promoter to Acquire 2.38% Stake via Inter-Se Transfer Worth Rs 100 Cr
Sachin D. Patel, a promoter of Gujarat Themis Biosyn Limited, has announced an intention to acquire up to 26,00,000 equity shares of the company, representing up to a 2.38% stake. The shares will be acquired from another promoter group entity, Themis Medicare Limited, via an inter-se transfer. The proposed transaction is valued at up to Rs. 100 crore and is scheduled to take place between June 30, 2026, and July 3, 2026. The acquisition price is set at Rs. 400.45 per share, which is a premium to the 60-day volume-weighted average market price of Rs. 369.15.
முக்கிய அம்சங்கள்
Proposed acquisition of up to 26,00,000 equity shares representing a 2.38% stake in Gujarat Themis Biosyn.Inter-se transfer between promoter group entities: Sachin D. Patel (Acquirer) and Themis Medicare Limited (Seller).Transaction value is estimated up to Rs. 100 crore at a proposed price of Rs. 400.45 per share.Post-transaction, Themis Medicare's stake will decrease from 23.19% to 20.81%, while Sachin D. Patel's stake will rise to 2.38%.
👀 கவனிக்க வேண்டியவை
This is an inter-se transfer within the promoter group and does not alter the overall promoter holding or trigger an open offer. Investors should treat this as a neutral liquidity realignment among promoters and continue to monitor the company's operational performance.
Gujarat Themis Biosyn Incorporates Step-down Subsidiary in Ireland
Gujarat Themis Biosyn Limited has successfully incorporated a new step-down subsidiary, Themis Biosyn Private Limited, in Ireland as of June 16, 2026. The new entity is a 100% subsidiary of Themis Biosyn Ireland Private Limited, which is already part of the company's group structure. With an initial share capital of 100 Euro, this move signals the company's strategic intent to expand its footprint in the international pharmaceutical market.
முக்கிய அம்சங்கள்
Incorporation of Themis Biosyn Private Limited in Ireland on June 16, 2026.The entity is a 100% step-down subsidiary of Gujarat Themis Biosyn Limited.Initial share capital for the new Irish entity is 100 Euro.The subsidiary will operate within the Pharmaceutical Industry, aligning with the parent's core business.The move follows the regulatory framework of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should view this as a long-term positive for international expansion, though immediate financial impact will be negligible given the nominal initial capital. Watch for future announcements regarding specific operational mandates or manufacturing/distribution licenses obtained by this Irish unit.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Gujarat Themis Biosyn to Seek Approval for Rs 1,000 Crore Fundraise via QIP
Gujarat Themis Biosyn Limited (GUJTHEM) has issued a postal ballot notice to seek shareholder approval for raising up to Rs 1,000 crore through a Qualified Institutions Placement (QIP). The fundraise may involve equity shares, warrants, or convertible debentures issued to eligible institutional buyers. The remote e-voting period for this special resolution is scheduled from June 9, 2026, to July 8, 2026. This significant capital infusion is likely intended to support the company's growth initiatives and strengthen its balance sheet.
முக்கிய அம்சங்கள்
Proposed fundraise of up to Rs 1,000 crore through QIP of equity shares or convertible securities.Shareholders' approval sought via postal ballot with e-voting concluding on July 8, 2026.Pricing will follow SEBI ICDR regulations with a potential discount of up to 5% on the floor price.The company may issue warrants or debentures with a maximum tenure of 60 months.The results of the postal ballot will be declared by July 10, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific end-use of the funds and the potential equity dilution once the QIP price and number of shares are finalized.
GUJTHEM Board Approves Fundraising of up to ₹1,000 Crores via QIP and Preferential Issue
Gujarat Themis Biosyn Limited has announced a major capital raising plan involving up to ₹1,000 Crores through a Qualified Institutions Placement (QIP). The board also approved a preferential issue of equity shares or warrants to non-promoter investors, with specific details to be finalized by a dedicated Fund-Raising Committee. These initiatives are subject to shareholder and regulatory approvals. The substantial fundraise suggests potential expansion or debt restructuring plans for the company.
முக்கிய அம்சங்கள்
Approved raising of funds aggregating up to ₹1,000 Crores through Qualified Institutions Placement (QIP).Authorized a preferential issue of equity shares to non-promoters in one or more tranches.The Fund-Raising Committee will determine the final number of securities and the issue price for the preferential allotment.The capital raise is subject to the approval of the company's members and necessary regulatory/statutory bodies.
👀 கவனிக்க வேண்டியவை
Investors should watch for the specific pricing of the QIP and the identity of the preferential allottees, as these will indicate institutional confidence. While the fundraise is positive for growth, shareholders should be mindful of the potential equity dilution resulting from these issuances.
Gujarat Themis Biosyn Limited (GUJTHEM) has successfully passed two special resolutions via postal ballot with over 98% majority. The resolutions authorize the company to increase borrowing limits and create charges on assets, as well as expand limits for loans, guarantees, and investments in other entities. While the resolutions passed due to strong promoter support, public institutional investors overwhelmingly voted against both proposals, with over 99.9% of their cast votes opposing the changes.
முக்கிய அம்சங்கள்
Resolution to increase borrowing limits under Section 180(1)(c) passed with 98.39% of total votes in favor.Resolution to approve limits for loans, guarantees, and investments passed with 98.38% favor.Significant institutional resistance observed, with public institutions casting 1,277,290 votes (99.95%) against both resolutions.Promoter group, holding 77.2 million shares, voted 100% in favor of the proposals.Total voter turnout for the postal ballot was approximately 72.8% of the 108.96 million total shares.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution and monitor the company's future capital allocation and debt-raising activities, as the near-unanimous institutional opposition suggests concerns regarding governance or potential di-worsification.
Gujarat Themis Biosyn Incorporates Wholly Owned Subsidiary in Ireland with €100,000 Capital
Gujarat Themis Biosyn Limited has successfully incorporated a new wholly owned subsidiary, Themis Biosyn Ireland Private Limited, in Ireland on May 29, 2026. The new entity is established within the pharmaceutical industry with an initial share capital of 1,00,000 Euro. This strategic move signifies the company's intent to expand its international footprint and operational presence in the European market. The parent company maintains 100% shareholding and control over the new subsidiary.
முக்கிய அம்சங்கள்
Incorporated a 100% Wholly Owned Subsidiary (WOS) named Themis Biosyn Ireland Private Limited in Ireland.The subsidiary has an initial share capital of 1,00,000 Euro.The entity will operate within the Pharmaceutical Industry, aligned with the parent company's core business.Official date of incorporation and business registration was May 29, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward global expansion and monitor future updates regarding the subsidiary's specific operational role and revenue contributions. Watch for management commentary on how this Irish base will facilitate entry into European pharmaceutical markets.
Gujarat Themis Q4 Revenue Up 17%; Announces Transformative ₹1,300 Cr Japan Acquisition
Gujarat Themis Biosyn (GTBL) reported Q4 FY26 revenue of ₹44.23 Cr, up 17.22% YoY, driven by robust sales volumes. The company announced two massive acquisitions: 13 brands from Sanofi for EUR 158 Mn and MicroBiopharm Japan for approximately ₹1,300 Cr, which are significantly larger than GTBL's current annual revenue of ₹165.82 Cr. While Q4 PAT fell 9.22% to ₹10.89 Cr due to higher interest and depreciation from ongoing capex, EBITDA margins remained strong at 43.77%. These acquisitions mark a strategic shift towards becoming a global fermentation-based CDMO with expanded therapeutic coverage.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue increased 17.22% YoY to ₹44.23 Cr; EBITDA rose 20.71% to ₹19.36 Cr.Acquiring MicroBiopharm Japan for ~₹1,300 Cr, adding advanced biotech platforms and Top 6 global pharma customers.Acquiring 13 Sanofi brands for EUR 158 Mn, adding EUR 62 Mn in revenue and access to 55+ countries.FY26 PAT stood at ₹46.68 Cr, a slight decline of 4.29% YoY due to expansion-related depreciation and interest.R&D investment reached 9% of topline in FY26, supporting the move into API and CDMO segments.
👀 கவனிக்க வேண்டியவை
The acquisitions are game-changers but will significantly increase debt and integration risk; long-term investors should focus on the CDMO transition. Monitor the funding mix and regulatory approvals for these large-scale deals as they will redefine the company's scale.
Gujarat Themis Biosyn Recommends Re 0.67 Dividend and Approves Preferential Share Issue
Gujarat Themis Biosyn has announced its audited financial results for the year ended March 31, 2026, alongside a final dividend recommendation of Re 0.67 per share. The company is also initiating a fundraise through a preferential issue of equity shares to non-promoters, signaling potential growth or expansion plans. A dedicated Preferential Issue Committee has been formed to finalize the terms, including the issue price and the number of securities to be issued. The total dividend payout is expected to be approximately Rs 7.30 crore, pending shareholder approval.
முக்கிய அம்சங்கள்
Recommended a final dividend of Re 0.67 per equity share (67% of face value) for FY 2025-26.Total dividend payout aggregates to Rs 7,30,06,728 subject to shareholder approval.Approved a proposal for preferential issue of equity shares/warrants to non-promoters.Constituted a Preferential Issue Committee to finalize pricing and allotment terms.Re-appointed M/s. Raja Dutta & Co. as Cost Auditor for the Financial Year 2026-27.
👀 கவனிக்க வேண்டியவை
Investors should look out for the specific pricing and investor names for the preferential issue as it will impact equity dilution and growth prospects. The dividend provides a steady return, but the capital raise is the primary catalyst for future valuation.
Gujarat Themis Biosyn to Acquire Japan's MicroBiopharm for ~INR 1,300 Crore
Gujarat Themis Biosyn Limited (GTBL) has announced the 100% acquisition of MicroBiopharm Japan (MBJ) for JPY 21.5 billion (approximately INR 1,300 crore). MBJ is a fermentation-based CDMO with estimated FY26 revenues of JPY 9.5 billion (INR 570 crore) and three FDA/PMDA approved manufacturing plants. The acquisition, funded through a mix of debt and equity, is expected to be EPS accretive and will transform GTBL into a globally integrated CDMO with advanced capabilities in ADC conjugation and Plasmid DNA. The transaction is expected to close by Q2 FY2027, subject to regulatory approvals.
முக்கிய அம்சங்கள்
Acquisition of 100% equity in MicroBiopharm Japan for JPY 21.5 Billion (~INR 1,300 Crore)MBJ reports FY26E revenue of JPY 9.5 Billion (~INR 570 Crore) with 40% revenue from outside JapanAcquisition includes 3 GMP-compliant plants with US FDA and PMDA approvalsTransaction expected to be EPS accretive and close by Q2 FY2027Enables entry into high-tech segments like ADC conjugation, Plasmid DNA, and precision fermentation
👀 கவனிக்க வேண்டியவை
This is a transformative acquisition that significantly scales GTBL's operations and technological capabilities. Investors should monitor the final debt-equity funding ratio and the company's ability to integrate the Japanese operations to realize projected synergies.
Gujarat Themis Biosyn to Acquire Japan's MBJ for INR 1,300 Crores
Gujarat Themis Biosyn (GTBL) has signed a definitive agreement to acquire 100% of MicroBiopharm Japan Co., Ltd. (MBJ) for approximately INR 1,300 crores (JPY 21.5 billion). MBJ is a specialized fermentation-based CDMO with an estimated FY26 revenue of INR 570 crores and expertise in oncology, peptides, and advanced modalities like ADCs. The acquisition, expected to close in Q2FY27, will be funded through a mix of debt and equity and is projected to be EPS accretive. This strategic move transforms GTBL from an intermediates manufacturer into a globally integrated, technology-driven CDMO platform.
முக்கிய அம்சங்கள்
Acquisition of 100% equity in MicroBiopharm Japan for JPY 21.5 billion (approx. INR 1,300 crores)MBJ recorded an estimated revenue of JPY 9.5 billion (approx. INR 570 crores) for FY26EGains access to advanced technologies including P450 enzyme library, Plasmid DNA, and ADC conjugationAcquisition includes two FDA and PMDA audited manufacturing sites in Japan, enhancing global regulatory reachManagement expects the transaction to be EPS accretive with a closing target of Q2FY27
👀 கவனிக்க வேண்டியவை
This is a transformative acquisition that significantly scales GTBL's revenue and technological capabilities; investors should monitor the final debt-equity mix used for funding. The entry into high-margin CDMO services and regulated markets like Japan and the US makes this a strong long-term growth catalyst.
Gujarat Themis Biosyn Incorporates Wholly Owned Subsidiary 'Themis Biosyn Japan Limited' in Japan
Gujarat Themis Biosyn Limited has announced the successful incorporation of a new wholly owned subsidiary in Japan, named Themis Biosyn Japan Limited. The subsidiary was officially incorporated on May 19, 2026, and the company received the Certificate of Registration on May 20, 2026. This strategic move marks the company's entry into the Japanese market, potentially opening new revenue streams for its biotechnology and pharmaceutical products. Investors should note this as a key step in the company's international expansion strategy.
முக்கிய அம்சங்கள்
Incorporation of a 100% wholly owned subsidiary in Japan.New entity named Themis Biosyn Japan Limited.Official date of incorporation recorded as May 19, 2026.Certificate of Registration received by the parent company on May 20, 2026.Move signifies strategic intent to expand global footprint in the pharmaceutical sector.
👀 கவனிக்க வேண்டியவை
Investors should monitor future disclosures regarding the specific business activities and capital expenditure planned for the Japanese subsidiary. This expansion is a positive long-term indicator of the company's growth ambitions beyond the Indian market.
Gujarat Themis Biosyn Incorporates Wholly Owned Subsidiary in Japan with 1M Yen Capital
Gujarat Themis Biosyn Limited has successfully incorporated a wholly owned subsidiary, Themis Biosyn Japan Limited, in Japan on May 19, 2026. The new entity is established with an initial share capital of 1,000,000 Yen and will operate within the pharmaceutical industry. This move marks a strategic international expansion for the company, aiming to establish a direct presence in the Japanese market. While the initial investment is modest, it signals management's intent to grow its global footprint and potentially explore new regulatory or commercial opportunities abroad.
முக்கிய அம்சங்கள்
Incorporated a 100% wholly owned subsidiary named Themis Biosyn Japan Limited on May 19, 2026.The subsidiary is established with a share capital of 1,000,000 Yen (approximately ₹5.3 lakhs).The entity will focus on the Pharmaceutical Industry, aligning with the parent company's core business.The incorporation follows compliance with Regulation 30 of SEBI Listing Regulations 2015.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive long-term strategic move into a major global pharmaceutical market. Monitor future quarterly updates for specific business activities or contracts originating from this Japanese subsidiary.
Gujarat Themis Biosyn Seeks Approval to Raise Borrowing & Investment Limits to ₹3,500 Crores
Gujarat Themis Biosyn Limited has issued a postal ballot notice seeking shareholder approval for a significant increase in its financial headroom. The company proposes to raise its borrowing limits to ₹3,500 Crores, allowing for various debt instruments including term loans, NCDs, and external commercial borrowings. Simultaneously, it is seeking a ₹3,500 Crore limit for providing loans, guarantees, or making investments in other corporate bodies. These moves suggest the management is preparing for substantial capital expenditure or strategic inorganic growth opportunities.
முக்கிய அம்சங்கள்
Proposed increase in borrowing limits to a maximum of ₹3,500 Crores under Section 180(1)(c).Request for authorization to create charges or mortgages on company assets up to the ₹3,500 Crore limit.Proposed limit for loans, guarantees, and investments in other entities set at ₹3,500 Crores under Section 186.Remote e-voting period is scheduled from May 6, 2026, to June 4, 2026.The results of the postal ballot are expected to be declared by June 8, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's subsequent announcements for specific project details or acquisition targets that necessitate such high financial limits. While the increased limits provide flexibility, actual debt utilization and the quality of new investments will be the primary drivers of long-term value.
Gujarat Themis Biosyn to Acquire Sanofi's Global Anti-TB Portfolio for €158 Million
Gujarat Themis Biosyn Limited (GTBL) has announced a major asset acquisition of Sanofi's global Anti-TB and Anti-Infective portfolio for approximately €158 million. The deal includes 13 established brands, such as Rifampicin and Rifapentine, which generated ~€62 million in revenue in FY 2025. This acquisition provides GTBL immediate access to over 55 countries across Europe and the MEA region. The transaction is structured as an asset-light model, funded by a mix of debt and equity, and is expected to be EPS accretive while enabling forward integration into APIs and finished dosages.
முக்கிய அம்சங்கள்
Acquisition of 13 established global brands from Sanofi for a total consideration of €158 millionAcquired portfolio reported revenue of ~€62 million for FY 2025 with healthy gross marginsImmediate global expansion into 55+ countries including regulated markets in Europe and MEAStrategic shift to an integrated 'Intermediate-to-API-to-FDF' model using existing fermentation strengthsPortfolio includes WHO Essential Medicines and EU Critical Drugs, ensuring resilient long-term demand
👀 கவனிக்க வேண்டியவை
This is a transformative deal that significantly scales GTBL's revenue and global footprint; investors should monitor the specific debt-equity mix for funding and the impact on interest coverage. Watch for regulatory approvals and the timeline for the integration of these brands into GTBL's existing fermentation-based manufacturing platform.
GUJTHEM Shareholders Approve Related Party Transactions and Director Re-appointment
Gujarat Themis Biosyn Limited (GUJTHEM) has successfully passed two key resolutions via postal ballot. The re-appointment of Mrs. Kirandeep Madan as an Independent Director received overwhelming support with 99.99% of votes in favour. However, the resolution for Material Related Party Transactions with Themis Medicare Limited saw significant resistance, passing with a narrow 52.56% majority among voting shareholders, while 47.44% voted against it. This high level of dissent on the RPT resolution indicates a segment of the minority shareholders has concerns regarding the company's dealings with its related entity.
முக்கிய அம்சங்கள்
Special Resolution for re-appointment of Mrs. Kirandeep Madan passed with 99.99% majority.Material Related Party Transactions (RPT) with Themis Medicare Limited approved with 52.56% votes in favour.Significant dissent on the RPT resolution with 47.44% of polled votes (1,258,122 shares) against the proposal.Total voter turnout for the RPT resolution was 2.43% of the total share capital, as promoters were interested parties.Public institutions showed high resistance to the RPT, with 98.46% of their polled votes being 'against'.
👀 கவனிக்க வேண்டியவை
Investors should scrutinize the terms of the related party transactions with Themis Medicare Limited given the high institutional dissent. While the resolutions passed, the narrow margin on the RPT suggests a need for closer monitoring of corporate governance and transaction transparency.
GUJTHEM Seeks Approval for ₹50 Cr Related Party Transactions and Director Re-appointment
Gujarat Themis Biosyn Limited has issued a postal ballot notice to seek shareholder approval for two key resolutions. The first resolution is the re-appointment of Mrs. Kirandeep Madan as an Independent Director for a second five-year term starting May 2026. The second resolution seeks approval for material related party transactions with Themis Medicare Limited (TML) totaling up to ₹50 Crores for the financial year 2026-27. The voting period is scheduled from March 19, 2026, to April 17, 2026, with results expected by April 21, 2026.
முக்கிய அம்சங்கள்
Proposed re-appointment of Mrs. Kirandeep Madan as Independent Director for a 5-year term until April 30, 2031.Seeking approval for Material Related Party Transactions with Themis Medicare Limited (TML) worth up to ₹50 Crores.The ₹50 Crores transaction limit is specifically for the upcoming Financial Year 2026-27.Remote e-voting period runs from March 19, 2026, to April 17, 2026.Transactions are intended to be conducted in the ordinary course of business and on an arm's length basis.
👀 கவனிக்க வேண்டியவை
Investors should review the terms of the related party transactions with Themis Medicare to ensure they align with the company's growth and margin objectives. No immediate action is required other than participating in the e-voting process if desired.
Gujarat Themis Biosyn Q3 Net Profit Dips 4% to ₹12.46 Cr; Appoints New CFO
Gujarat Themis Biosyn reported a 10.1% year-on-year increase in total income to ₹43.78 crore for Q3 FY26. However, net profit for the quarter declined by 3.9% to ₹12.46 crore, primarily due to a significant rise in depreciation and employee benefit expenses. The company also announced a management transition, with Krupesh Patel appointed as the new CFO effective April 1, 2026, as the current CFO moves to a plant-level accounting role. The 9-month net profit stands at ₹35.79 crore, slightly lower than the ₹36.77 crore recorded in the previous year.
முக்கிய அம்சங்கள்
Total Income for Q3 FY26 rose to ₹4,378.45 Lakhs from ₹3,976.15 Lakhs in Q3 FY25.Net Profit after tax decreased to ₹1,246.46 Lakhs compared to ₹1,297.23 Lakhs in the same quarter last year.Depreciation and Amortization expenses more than doubled to ₹388.81 Lakhs from ₹156.33 Lakhs YoY.Mr. Krupesh Patel, an MBA/CS/ICWA professional, is appointed as CFO effective April 1, 2026.A one-time financial impact of ₹13.36 lakhs was recognized following the notification of new Labour Codes.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to scale revenue to offset the rising depreciation costs associated with recent capital expenditures. The stock remains a hold as core operations show steady revenue growth despite temporary margin pressure.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
